money moves

Houston health tech startup closes $10M series B led by Austin investors

BrainCheck has raised its latest round of funding. Photo by Natalie Harms/InnovationMap

A Houston-based tech company that's tackling cognitive health diagnoses with its innovative platform has closed its latest round of funding.

BrainCheck, the cognitive health care platform for physicians, announced the closing of its $10 million series B funding led by Austin-based investors, Next Coast Ventures and S3 Ventures. The funding will be used to expand research and development, including developing a digital therapeutic and enhancing go-to-market capabilities.

BrainCheck's digital platform allows physicians to better assess cognitive function in their patients — whether they are elderly dementia patients or suffering from other cognitive ailments. One in nine adults aged 45 and older report subjective cognitive decline, according to a news release, and one in 14 COVID-19 survivors have neurocognitive disorder.

"We are at the forefront of improving access to cognitive assessment and care," says Yael Katz, co-founder and CEO of BrainCheck, in the release. "With early diagnosis comes treatment and intervention. These funds will allow us to accelerate the adoption of our platform and work with clinicians to help more patients live better and safer lives, decrease caregiver frustration, and save health systems trillions of dollars. I believe that BrainCheck can help cognitive care evolve the way cancer care has since the 1970s, when chemotherapy was one-size-fits-all."

Katz co-founded the company with neuroscientist David Eagleman in January of 2015. Now, doctors at over 400 neurology, primary care and geriatrics practices — such as Cleveland Clinic, MD Anderson, and Johns Hopkins — are already using BrainCheck's 10-to-15-minute test, which is covered by Medicare and by most private insurers, to conduct cognitive testing. The FDA Class II Software as a Medical Device (SaMD), which means that physicians can facilitate in-person or even an remote assessment of their patients' cognitive function.

"BrainCheck is a breakthrough platform that has the potential to transform how we diagnose and treat cognitive impairment," says Michael Smerklo, co-founder and managing director of Next Coast Ventures, in the release. "The combination of technical sophistication and ease of use makes BrainCheck a perfect tool for doctors and health systems everywhere. I'm so impressed by what Dr. Katz and her team have achieved to date and am excited to support the team as they continue to innovate and scale."

Other investors included Nueterra Capital, Tensility Ventures, and True Wealth Ventures, as well as UPMC Enterprises and SelectQuote, which joined on as strategic investors.

"BrainCheck shows promise as a cognitive assessment tool that would allow patients to independently complete the test while allowing physicians to spend more time reviewing the results and planning care with patients," says Dr. Adele Towers, director of risk adjustment at UPMC Enterprises and a geriatric medicine specialist at UPMC, in the release.

BrainCheck closed its $8 million series A round in October of 2019, and the company moved into its new office in Upper Kirby following the raise in early 2020. The startup also has an office in Austin.

Trending News

 
 

Promoted